NCT04053322: A Phase I/II Trial Assessing Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.

NCT04053322
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: BRCA+, DNA damage repair mutations, ATM, AKT, ESR1, FGFR, PI3K
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Misc Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have one of the mutations listed
Exclusions: Patients with symptomatic uncontrolled brain metastases that require treatment- see trial for details; Patients who have had prior treatment with a PARP inhibitor (including olaparib) and/or PD-1/L1 inhibitor (including durvalumab)
https://ClinicalTrials.gov/show/NCT04053322

Comments are closed.

Up ↑